
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is supported by its strong partnership with Chiesi, a projected launch of Seralutinib in the second half of 2027, and positive support from KOLs who view PROSERA as a successful treatment under p<0.05 and are eager for another mechanism of action, and the potential for a differentiated inhaled TKI. While the recent debt restructuring may be dilutive, Gossamer's long-term financial viability is supported by its debt reduction and additional financings. Potential risks include clinical development and commercialization risks, pricing and reimbursement risks, and potential disruptions to clinical trials in Eastern Europe.
Bears say
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics in the areas of immunology, inflammation, and oncology. However, the recent Phase 3 results for their lead candidate, seralutinib, failed to meet the primary endpoint of improved median change in 6-minute walk distance at 24 weeks, causing concern about the drug's potential for regulatory approval and commercial success. In addition, the company's existing convertible debt and potential need for additional financing also adds uncertainty to their financial future. Therefore, a neutral outlook is warranted until there is more clarity on the drug's potential and the company's financial situation.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares